Marta Von Horoch

Marta Von Horoch

Auto-generated profile, based on publicly available information

Marta Von Horoch

General Directorate of Health Surveillance, Ministry of Public Health and Social Welfare , Asunción

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2025 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PCPaula Couto
Paula Couto
AAAlejandra Acevedo
Alejandra Acevedo
BHBelsy Acosta Herrera
Belsy Acosta Herrera
OAOlaya Astudillo
Olaya Astudillo
MAMartín Avaro
Martín Avaro
AVAndrea S Vicari
Andrea S Vicari
: The Surveillance Network for Influenza and Other Respiratory Viruses (SARInet) has played a crucial role in improving the capacity of Latin American countries to monitor and respond to events with potential public health impact. This perspective compiles and analyzes case studies from several countries in the Americas to illustrate the challenges faced prior to the creation of SARInet, the interventions implemented, and the impacts achieved. Methodology: This study is based on a series of cases from 12 countries in Latin America and the Caribbean. The data have been compiled from reports, ad-hoc assessments and technical group analyses conducted before and after the implementation of SARInet in 2014. Results: Over the past decade, SARInet has been instrumental in strengthening the capacity for early detection and response to public health events in several Latin American countries. Technical cooperation in epidemiological and laboratory surveillance, personnel training, intersectoral coordination and the adoption of advanced technologies have improved the countries' capacity for timely detection and management of epidemic and pandemic outbreaks. Conclusions: The experience of the countries shows that regional collaboration and the strengthening of local capacities are essential to face future public health challenges.

15 December 2021 in Pediatría (Asunción)
Verified
Journal Article
Open access
PDF file
SASoraya Araya
Soraya Araya
TPTeresa Perez
Teresa Perez
ATAvelina Troche
Avelina Troche
JNJulio Nissen
Julio Nissen
LCLuis Cousirat
Luis Cousirat
HCHéctor Castro
Héctor Castro
Introducción: La pandemia de COVID-19 produjo una crisis sanitaria afectando las coberturas de vacunación de los países. Objetivo: Describir la cobertura de vacunación de los biológicos trazadores durante el periodo prepandémico (2015- 2019) y pandémico (2020-2021) en Paraguay. Materiales y Métodos: Estudio descriptivo observacional de corte transverso, que comprendió a niños de 0 a 5 años de edad, de las 18 Regiones Sanitarias del País. Se analizaron las coberturas de vacunación del Programa Ampliado de Inmunización, periodo prepandémico (2015-2019) y pandémico (2020-201). Se incluyeron los biológicos trazadores: BCG, DPT1, DPT3, IPV1 y bOPV3, SPR1, SPR2 y vacuna antiamarílica (AA), el cálculo de cobertura de vacunación a nivel país se realizó por medio del análisis del reporte electrónico semanal de dosis de vacunas administradas por Región Sanitaria. Se estableció la comparación de las coberturas de vacunación por biológico trazador, por periodos y rango de edad. Resultados: Durante la pandemia se constató un descenso de cobertura de vacunación de los biológicos trazadores, para BCG: 4 % (2020), 15% (2021);DPT1: 5 % (2020), 13 % (2021); DPT3: 9 % (2020), 22 %(2021); IPV1: 5 % (2020),16 % (2021); bOPV3: 7% (2020),19 % (2021); SPR1: 9 %, SPR2: 13 % (2020),SPR1:17%, SPR2:16 % (2021) y AA: 7% (2020), 15% (2021).Conclusión: Durante la pandemia de Covid-19 disminuyeron las coberturas de vacunación de todos los biológicos trazadores, similar descenso se constató en otros países de América, existe el riesgo de aparición de brotes de enfermedades prevenibles por vacunación por el acúmulo de susceptibles. Conflicto de interés: los autores declaran no poseer conflicto de interés, se aclara que ninguno trabaja para laboratorios fabricantes de vacunas. Fuente de financiamiento: autofinanciado Recibido: 25/10/2021 Aceptado: 19/11/2021

15 September 2023 in Vaccine
Verified
Journal Article
Closed access
SISandra Irala
Sandra Irala
SHSarah Hamid
Sarah Hamid
EPElena Penayo
Elena Penayo
FMFabiana Michel
Fabiana Michel
PCPaula Couto
Paula Couto
FNFrancisco Nogareda
Francisco Nogareda

10 March 2025 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
JJJorge H Jara
Jorge H Jara
SLSergio Loayza
Sergio Loayza
FNFrancisco Nogareda
Francisco Nogareda
PCPaula Couto
Paula Couto
MDMiguel Angel Descalzo
Miguel Angel Descalzo
DSDaniel Salas
Daniel Salas
Background: To better establish the value of vaccination against influenza viruses, we estimated vaccine-averted influenza illnesses among young children and older adults in Chile, Guyana, and Paraguay. Methods: We gathered country- and target population-specific data on monthly influenza hospitalizations, vaccine coverage, and vaccine effectiveness from surveillance records and immunization registries during 2013–2018. We applied a static compartmental model to estimate differences in the number influenza-associated respiratory disease events (symptomatic nonhospitalized illnesses, medically attended illnesses, hospitalizations) in the presence and absence of influenza vaccination programs. Results: Between 2013 and 2018, vaccinating 68% of children aged 6–23 months in Chile averted an annual mean of 14 617 nonhospitalized, 9426 medically attended, and 328 hospitalized influenza illnesses; vaccinating 28% of children aged 6–23 months in Paraguay averted 1115 nonhospitalized, 719 medically attended, and 25 hospitalized influenza illnesses. Vaccinating 59% of older adults in Chile averted an annual mean of 83 429 nonhospitalized, 37 079 medically attended, and 1390 hospitalized influenza illnesses; vaccinating 36% of older adults in Paraguay averted an annual mean of 3932 nonhospitalized, 1748 medically attended, and 66 hospitalized influenza illnesses. In Guyana, a hypothetical campaign vaccinating 30% of children aged <5 years could have prevented an annual 1496 nonhospitalized, 971 medically attended, and 10 hospitalized influenza illnesses. Vaccinating 30% of adults aged ≥65 years could have prevented 568 nonhospitalized, 257 medically attended, and 10 hospitalized influenza illnesses. Conclusions: Influenza vaccination averted tens of thousands of illnesses and thousands of hospitalizations in Chile and Paraguay; influenza vaccination could have had a proportional benefit in Guyana.

10 March 2025 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
MDMiguel Angel Descalzo
Miguel Angel Descalzo
FJFrancisco José de Paula Júnior
Francisco José de Paula Júnior
NMNatalia Vergara Mallegas
Natalia Vergara Mallegas
EPElena Penayo
Elena Penayo
CVCarla Voto
Carla Voto
PCPaula Couto
Paula Couto
Background: We estimate annual viral influenza-associated mild-to-moderate illness, hospitalizations, and deaths in 6 South American countries (Argentina, Brazil, Chile, Ecuador, Paraguay, and Uruguay) during the 2015–2019 influenza seasons as a first step in evaluating the full value of influenza vaccination in the subregion. Methods: We applied a multiplier method using monthly hospital discharge and vital statistics death records, influenza surveillance data, and population projections to estimate mild-to-moderate influenza-associated illness, hospitalizations, and deaths. We estimated the uncertainty bounds based on the 2.5th and 97.5th percentiles of the Monte Carlo simulated distributions for the number of cases and obtained the ranges from the minimum value of the 2.5th and the maximum value of the 97.5th percentile. Results: In selected countries with a total population of 307 million people, the yearly influenza-associated burden of disease ranged between 51 and 78 million mild-to-moderate influenza illnesses, between 323 379 and 490 049 hospitalizations, and between 22 662 and 46 971 deaths during the 2015–2019 influenza seasons. Conclusions: Each year, influenza is associated with millions of illnesses, hundreds of thousands of hospitalizations, and tens of thousands of deaths in 6 South American countries, affecting a significant portion of the population. Such findings can be used to estimate the number of illnesses averted through vaccination programs and the cost-benefit of influenza vaccines.

31 August 2024 in Pediatría (Asunción)
Verified
Journal Article
Open access
PDF file
SYSoraya Araya Yampey
Soraya Araya Yampey
JBJorge López Benitez
Jorge López Benitez
LSLuis Cousirat Sanabria
Luis Cousirat Sanabria
RMRocío Britos Martínez
Rocío Britos Martínez
HLHéctor Castro Leguizamón
Héctor Castro Leguizamón
JAJulio Nissen Abente
Julio Nissen Abente
Introducción: A nivel mundial, el cáncer de cuello uterino es el cuarto cáncer más frecuente en la mujer. Objetivo: Describir las coberturas anuales de vacunación contra VPH y ESAVI. Material y Métodos: Estudio observacional descriptivo transversal, realizado en Paraguay, periodo 2013-2023, variables analizadas: coberturas de vacunación contra VPH en niñas de 10 años, según esquema: 3 dosis (2013-2016), 2 dosis (2017-2023), coberturas de vacunación de seguimiento a los 15 años (1ª dosis y Dosis Final), ESAVI grave y no grave. Resultados: Los intervalos de coberturas de vacunación contra VPH 1ª dosis: 55-73% (periodo no pandémico), 33-53 % (periodo pandémico), mientras que para Dosis Final: 1-64% (periodo prepandémico) y 5-31 % (periodo pandémico). Al analizar las coberturas de vacunación contra VPH Dosis Final según esquema el promedio de deserción fue mayor en esquema de 3 dosis: 42 vs 25% (valor p= 0,001). El intervalo de coberturas de seguimiento a los 15 años Dosis Final: 66 a 77%. Hubo un recupero importante en los años 2019-2021: 71%, 65% y 59% respectivamente. La Tasa de ESAVI: 2,5 x 100.000 dosis administradas. Conclusión: Las coberturas de vacunación de seguimiento a los 15 años fueron < 90%. La tasa de ESAVI por 100.000 fue baja.